These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

37 related articles for article (PubMed ID: 12736232)

  • 21. High-dose ifosfamide in combination with etoposide and epirubicin (IVE) in the treatment of relapsed/refractory Hodgkin's disease and non-Hodgkin's lymphoma: a report on toxicity and efficacy.
    Proctor SJ; Taylor PR; Angus B; Wood K; Lennard AL; Lucraft H; Carey PJ; Stark A; Iqbal A; Haynes A; Russel N; Leonard RC; Culligan D; Conn J; Jackson GH
    Eur J Haematol Suppl; 2001 Jul; 64():28-32. PubMed ID: 11486397
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High dose ifosfamide in combination with etoposide and epirubicin followed by autologous stem cell transplantation in the treatment of relapsed/refractory Hodgkin's disease: a report on toxicity and efficacy.
    Jackson GH; Angus B; Carey PJ; Finney RD; Galloway MJ; Goff DK; Haynes A; Lennard AL; Leonard RC; McQuaker IG; Proctor SJ; Russell N; Windebank K; Taylor PR;
    Leuk Lymphoma; 2000 May; 37(5-6):561-70. PubMed ID: 11042516
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ifosfamide, epirubicin, etoposide (IEV) and autologous peripheral blood progenitor cell transplant: a feasible and effective salvage treatment for lymphoid malignancies.
    Clavio M; Garrone A; Pierri I; Michelis GL; Balocco M; Albarello A; Varaldo R; Canepa P; Miglino M; Ballerini F; Canepa L; Gobbi M
    Oncol Rep; 2005 Oct; 14(4):933-40. PubMed ID: 16142354
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dose-Modified Ifosfamide, Epirubicin, and Etoposide is a Safe and Effective Salvage Therapy with High Peripheral Blood Stem Cell Mobilization Capacity for Poorly Mobilized Hodgkin's Lymphoma and Non-Hodgkin's Lymphoma Patients.
    Fukunaga A; Hyuga M; Iwasaki M; Nakae Y; Kishimoto W; Maesako Y; Arima N
    J Clin Exp Hematop; 2016; 56(1):50-4. PubMed ID: 27334858
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Outpatient-based ifosfamide, carboplatin and etoposide (ICE) chemotherapy in transplant-eligible patients with non-Hodgkin's lymphoma and Hodgkin's disease.
    Hertzberg MS; Crombie C; Benson W; Taper J; Gottlieb D; Bradstock KF
    Ann Oncol; 2003; 14 Suppl 1():i11-6. PubMed ID: 12736225
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hodgkin's lymphoma: what is next in salvage treatment?
    Gisselbrecht C
    Ann Oncol; 2003; 14 Suppl 1():i37-8. PubMed ID: 12736229
    [No Abstract]   [Full Text] [Related]  

  • 27. Strategic approach to the management of Hodgkin's disease incorporating salvage therapy with high-dose ifosfamide, etoposide and epirubicin: a Northern Region Lymphoma Group study (UK).
    Proctor SJ; Jackson GH; Lennard A; Angus B; Wood K; Lucraft HL; White J; Windebank K; Taylor PR;
    Ann Oncol; 2003; 14 Suppl 1():i47-50. PubMed ID: 12736232
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ifosfamide, epirubicin and etoposide (IEV) in non-Hodgkin's lymphoma and Hodgkin's disease: the Italian experience.
    Zinzani PL
    Ann Oncol; 2003; 14 Suppl 1():i43-5. PubMed ID: 12736231
    [No Abstract]   [Full Text] [Related]  

  • 30. New perspectives in the treatment of non-Hodgkin's lymphoma.
    Goss PE
    Semin Oncol; 1992 Dec; 19(6 Suppl 12):23-9. PubMed ID: 1485171
    [TBL] [Abstract][Full Text] [Related]  

  • 31. European experience with ifosfamide in lymphomas.
    von Kalle AK; Schaadt M; Diehl V
    Semin Oncol; 1989 Feb; 16(1 Suppl 3):73-7. PubMed ID: 2468184
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ifosfamide salvage treatment before autologous stem cell transplantation in patients with refractory and relapsed Hodgkin's lymphoma: a GELA experience.
    Gisselbrecht C; Mounier N; Fermé C; Brice P
    Ann Oncol; 2003; 14 Suppl 1():i39-41. PubMed ID: 12736230
    [No Abstract]   [Full Text] [Related]  

  • 33.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 34.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 35.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 36.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 37.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]     [New Search]
    of 2.